What's Next for Lipoprotein(a) Lowering Agent SLN360
Steve Nissen, MD, reviews the promising phase 1 APOLLO findings, and details what needs to be investigated next for the siRNA.
Evidence Builds for Bentracimab Reversing Antiplatelet Effect of Ticagrelor
Deepak L. Bhatt, MD, MPH, reviews the latest phase 2b trial data supporting the fast-acting monoclonal antibody infusion for bleeding risk reversal.
Rivaroxaban Benefits LER Patients Safely Regardless of Chronic Kidney Disease
VOYAGER PAD subgroup analyses showed the anticoagulant reduced likelihood of hospitalization without increasing bleeding risk in patients with CKD.
Vupanorsen Falls Short Despite HDL-C Reduction in TRANSLATE-TIMI 70
Study author Brian Bergmark, MD, discusses what's next for the ANGTYL3 inhibitor, as well as promising developments in lipid-targeting therapies.
The Immediate Impact of the 2022 Heart Failure Guidelines
Larry Allen, MD, explains the significance of introducing SGLT-2 inhibitor recommendations to various stages of heart failure treatment and prevention guidelines.
Milind Desai, MD: Next Steps for Mavacamten for Hypertrophic Cardiomyopathy
Desai discusses the potential long-term effects of mavacamten and what it could mean for a patient population with HCM.
How New Heart Failure Guidelines Recommend SGLT-2 Inhibitor Use
Guideline writing committee co-chair Biykem Bozkurt, MD, PhD, discusses the utility of the drug class in HF prevention and risk reduction.
Will a Drug Get Approved for Epidermylosis Bullosa?
A pair of novel topical drugs hit high phase 3 marks at AAD 2022. One expert explains how they both may reach ground-breaking indications.
Advancing Pediatric Dermatology Biologics and Symptom Scoring
Amy S. Paller, MD, concludes her AAD 2022 interview with a look into the future of pediatric systemic therapy—and a call to assure due diligence in tracking patient progression among her peers.
Oleogel-S10 Significantly Improves Epidermolysis Bullosa Wounds at 12 Months
Dedee F. Murrell, MD, details the EASE trial findings presented at AAD 2022, and what the benefit of the novel topical gel may mean for patients with EB.
Ritlecitinib Generally Safe and Tolerated for Alopecia Areata
The ALLEGRO study detailed the efficacy and safety of ritlecitinib in adult and adolescent patients with the alopecia areata.
Dupilumab, Biologics for the Youngest Atopic Dermatitis Patients
The agent may become approved this year for children aged 6 months to 5 years old. Amy S. Paller, MD, discusses what impact it could bring.
Detailing Potential Dermatology Drug Approvals from AAD 2022
Dr. Raj Chovatiya provides updates from AAD on some pending and potential FDA approvals for several dermatology therapies.
Baricitinib Treatment Leads to Hair Regrowth in Alopecia Areata
With no approved therapies currently available, Dr. Brett King feels that the JAK inhibitor baricitinib could provide patients with a long sought after solution to hair loss.
Topical Gene Therapy B-VEC Reaches Phase 3 Efficacy Endpoints for DEB Disease Reversal
New AAD 2022 data show the novel gene therapy from Krystal Biotech provided wound healing by 3 months in patients with dystrophic epidermolysis bullosa.
The Potential of Dupilumab Treatment for Prurigo Nodularis
Dr. Gil Yosipovitch suspects that dupilumab will be approved for use in patients with prurigo nodularis based on new data from the LIBERTY-RN PRIME2 trial.
Amy S. Paller, MD: Systemic Atopic Dermatitis Therapy for Pediatric Patients
The Feinberg School of Medicine expert discusses the impact of dupilumab and other biologics on severely affected children and adolescnets.
How Autoimmune Disease Risks Heightens After SARS-CoV-2
An expert delves into the increased risk of conditions including psoriasis flares, lupus, and scleroderma following COVID-19.
Addressing Cardiometabolic Disease in Patients with Psoriasis
New phase 4 data suggests that apremilast could be used to improve cardiometabolic function in patients with psoriatic disease.
Positive Long-Term Safety Data for Tralokinumab in Patients with AD
Data from the 5-year extension trial ECZTEND indicated that the overall safety profile of tralokinumab was consistent with the previous ECZTRA trials.
The Promise of Ruxolitinib Cream for Vitiligo Repigmentation
Dr. David Rosmarin follows up his AAD presentation with an interview on ruxolitinib cream for facial and body repigmentation in patients with vitiligo.
Awaiting FDA Decision on Ruxolitinib Cream for Vitiligo
John E. Harris, MD, PhD, discusses the delayed decision date for the topical JAK inhibitor, and what more needs to be researched on the drug.
The Promising Future of Vitiligo Treatment
John E. Harris, MD, PhD, explains how JAK inhibitors and biologic therapy may advance the field from "Iron Age" era treatment strategy.
Atopic Dermatitis Linked to Increased Risk of Select Cancers
The increased risk of cancer development in patients with atopic dermatitis has been suggested due to chronic inflammation or immunologic defects inherent to the disease and various treatments.
VISIBLE Study Dedicated Entirely to Psoriasis Patients with Skin of Color
Dr. Daphne Chan spoke of representation in psoriasis trials, how psoriasis affects different skin types, and how the VISIBLE study can influence dermatology research at large.
Jan Wehkamp, MD, PhD: The Promise of Biologics for IBD
The advent of biologics has transformed care for patients with inflammatory bowel disease.
Institutional Perspectives in Psychiatry: Addressing Challenges in Depression Treatment
Subhdeep Virk, MBBS, chaired the recent State of the Science event on treatment-resistant depression.
The Impact of a Pegcetacoplan FDA Approval for Geographic Atrophy
After more promising long-term data, Apellis announced plans to seek regulatory approval. An investigator explains what value it could bring to patients.
Axel Dignass, MD, PhD: The Promising Future of Guselkumab
Approximately 60% of patients with ulcerative colitis treated with guselkumab achieved clinical remission.
FT218 Improves Sleep Quality, Daytime Sleepiness in Narcolepsy Patients
New data on FT218 will be presented at the World Sleep 2022 conference in Rome.